Details of the Drug

General Information of Drug (ID: DMRDZ4X)

Drug Name
Dabigatran etexilate
Synonyms
BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
Indication
Disease Entry ICD 11 Status REF
Venous thromboembolism BD72 Phase 3 [1]
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 627.7
Logarithm of the Partition Coefficient (xlogp) 5.3
Rotatable Bond Count (rotbonds) 18
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Bioavailability
The bioavailability of drug is 3-7% [2]
Elimination
Dabigatran is primarily eliminated in the urine, 7% of the radioactivity is recovered in urine and 86% is recovered in feces [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 - 17 hours [2]
Metabolism
The drug is metabolized via plasma [3]
Vd
The volume of distribution (Vd) of drug is 50-70 L [2]
Chemical Identifiers
Formula
C34H41N7O5
IUPAC Name
ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
Canonical SMILES
CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4
InChI
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
InChIKey
KSGXQBZTULBEEQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135565674
CAS Number
211915-06-9
DrugBank ID
DB06695
TTD ID
D0KI5R
INTEDE ID
DR0400
ACDINA ID
D00162

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [4]
Carboxylesterase 1 (CES1)
Main DME 		DEB30C5 EST1_HUMAN Substrate [5]
Carboxylesterase 2 (CES2)
Main DME 		DETHCPD EST2_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Potassium chloride E00074 4873 Tonicity agent
Sunset yellow FCF E00255 17730 Colorant
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
Carrageenan E00714 Not Available Emulsion stabilizing agent; Gelling agent; Microencapsulating agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Dimethicone 350 E00706 Not Available Antifoaming agent; Emollient; Water-repelling agent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dabigatran etexilate 150 mg capsule 150 mg Oral Capsule Oral
Dabigatran Etexilate Mesylate eq 110mg base capsule eq 110mg base Capsule Oral
Dabigatran Etexilate Mesylate eq 150mg base capsule eq 150mg base Capsule Oral
Dabigatran Etexilate Mesylate eq 75mg base capsule eq 75mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 FDA Approved Drug Products: PRADAXA (dabigatran) oral pellets
3 Szultka M, Krzeminski R, Jackowski M, Buszewski B: Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC-ESI/MS. Chromatographia. 2014;77:1027-1035. doi: 10.1007/s10337-014-2648-2. Epub 2014 Mar 22.
4 Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
5 Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.